mixngo the disruptive technology, page-14

Quanterix, due to their funding by global companies and personal contacts to the giants in the diagnostic field ( as outlined today ), could well be a gate into large commercialised applications of our technology.

I had since considerable time assumed that the waiting periods to crack into existing programs might be a very timely issue, whereas to be part of new systems and technologies would create a wider and broader implementation within an innovative push in the industry.

If this should eventuate, ADO will become a major biotech player in Australia.